ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Gout & Cardiometabolic Co-Morbidities

Jason Liebowitz, MD, FACR  |  October 28, 2025

ACR 2025 experts explore gout’s deep ties to MetS, insulin resistance & cardiovascular mortality, weighing new data on colchicine, febuxostat & SGLT2 inhibitors.

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 27, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Promising Combination Treatment for Gout

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2025

The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.

FDA Approves 2 More Denosumab Biosimilars

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2025

The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.

The 2025 ACR Awards of Distinction

Patrice Fusillo  |  October 25, 2025

The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.

The 2025 ARP President’s & Merit Awards

Patrice Fusillo  |  October 25, 2025

Meet the 2025 ARP President’s & Merit Award recipients honored for their significant contributions to rheumatology research, education & patient care.

The ACR Names 16 New Masters

Patrice Fusillo  |  October 25, 2025

The ACR recognizes 16 members with its highest honor. See the 2025 class of ACR Masters & read their personal reflections on this career milestone.

ACR Honors Distinguished Fellows: Class of 2025

Patrice Fusillo  |  October 25, 2025

Meet the 10 clinical & research fellows named 2025 ACR Distinguished Fellows. Learn what this prestigious honor means to them & their work.

The Rheum Advocate: A Fresh Look for the Same Trusted Voice

From the College  |  October 21, 2025

Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.

ACR Delegation to Address AI, Non-Compete Agreements at Interim AMA House of Delegates Meeting

From the College  |  October 21, 2025

The ACR’s resolutions at the Interim HOD meeting, held Nov. 14–18, will address non-compete agreements as well as the use of artificial intelligence (AI) in prior authorization processes.

  • 1
  • 2
  • 3
  • …
  • 834
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences